Skip to Main Content

Paper Details

The evolution of RET inhibitor resistance in RET-driven lung and thyroid cancers.
Nat Commun
45
2022
Author NameAffiliation
Selcuk Onur SumerMarie-Josee and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center
Marc LadanyiMemorial Sloan Kettering Cancer Center
Eric J ShermanMemorial Sloan Kettering Cancer Center
Michael F BergerMemorial Sloan Kettering Cancer Center
Michael F BergerMarie-Josee and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center
Michael F BergerWeill Cornell Medical College
Barry S TaylorMarie-Josee and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center
Barry S Taylor
Barry S TaylorWeill Cornell Medical College
Barry S TaylorMemorial Sloan Kettering Cancer Center
Barry S TaylorMemorial Sloan Kettering Cancer Center
Barry S TaylorMarie-Josee and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center
Barry S TaylorMemorial Sloan Kettering Cancer Center
Barry S TaylorMemorial Sloan Kettering Cancer Center
Barry S TaylorWeill Cornell Medical College
Barry S Taylor
Alexander DrilonMemorial Sloan Kettering Cancer Center
  • 1 - 17

Datasets

Release 1.2